DOI QR코드

DOI QR Code

Drug Resistance Effects of Ribosomal Protein L24 Overexpression in Hepatocellular Carcinoma HepG2 Cells

  • Guo, Yong-Li (Oncology Department of the Jining First People's Hospital) ;
  • Kong, Qing-Sheng (Department of Scientific Research) ;
  • Liu, Hong-Sheng (Intensive Care Unit of Affiliated Hospital of Jining Medical University) ;
  • Tan, Wen-Bin (Department of Pathogenic Biology, Jining Medical University)
  • 발행 : 2014.12.18

초록

Background: The morbidity and mortality rate of liver cancer continues to rise in China and advanced cases respond poorly to chemotherapy. Ribosomal protein L24 has been reported to be a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cell growth of cancer. Materials and Methods: Total RNA of cultured amycin-resistant and susceptible HepG2 cells was isolated, and real time quantitative RT-PCR were used to indicate differences between amycin-resistant and susceptible strains of HepG2 cells. Viability assays were used to determine amycin resistance in RPL24 transfected and control vector and null-transfected HepG2 cell lines. Results: The ribosomal protein L24 transcription level was 7.7 times higher in the drug-resistant HepG2 cells as compared to susceptible cells on quantitative RT-PCR analysis. This was associated with enhanced drug resistance as determined by methyl tritiated thymidine (3H-TdR) incorporation. Conclusions: The ribosomal protein L24 gene may have effects on drug resistance mechanisms in hepatocellular carcinoma HepG2 cells.

키워드

참고문헌

  1. Barkic M, Crnomarkovic S, Grabusic K, et al (2009). The p53 tumor suppressor causes congenital malformations in Rpl24- deficient mice and promotes their survival. Mol Cell Biol, 29, 2489-504. https://doi.org/10.1128/MCB.01588-08
  2. Chan YL, Olvera J, Wool IG (1994). The primary structure of rat ribosomal protein L24. Biochem Biophys Res Commun, 202, 1176-80. https://doi.org/10.1006/bbrc.1994.2052
  3. Chen YT, Feng B, Chen LB (2012). Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev, 13, 3577-81. https://doi.org/10.7314/APJCP.2012.13.8.3577
  4. Enooku K, Tateishi R, Kanai F, et al (2012). Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times. J Gastroenterol, 47, 71-8. https://doi.org/10.1007/s00535-011-0462-2
  5. Haque ME, Elmore KB, Tripathy A, et al (2010). Properties of the C-terminal tail of human mitochondrial inner membrane protein Oxa1L and its interactions with mammalian mitochondrial ribosomes. J Biol Chem, 285, 28353-62. https://doi.org/10.1074/jbc.M110.148262
  6. Hou X, Peng JX, Hao XY, et al (2013). DNA Methylation Profiling Identifies EYA4 Gene as a Prognostic Molecular Marker in Hepatocellular Carcinoma. Ann Surg Oncol.
  7. Huang YH, Chen ZK, Huang KT, et al (2013). Decreased expression of LKB1 correlates with poor prognosis in hepatocellular carcinoma patients undergoing hepatectomy. Asian Pac J Cancer Prev, 14, 1985-8. https://doi.org/10.7314/APJCP.2013.14.3.1985
  8. Kataoka K, Kanazawa A, Iwamoto S, et al (2014). Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease? World J Surg, 38, 936-46. https://doi.org/10.1007/s00268-013-2305-1
  9. Kim Y, Kim HD, Youn B, Park YG, Kim J (2013). Ribosomal protein S3 is secreted as a homodimer in cancer cells. Biochem Biophys Res Commun, 441, 805-8. https://doi.org/10.1016/j.bbrc.2013.10.132
  10. Liu H S, Tan W B, Yang N, et al (2014). Effects of ribosomal protein l39-L on the drug resistance mechanisms of lung cancer A549 cells. Asian Pac J Cancer Prev, 15, 3093-7. https://doi.org/10.7314/APJCP.2014.15.7.3093
  11. Llovet JM (2014). Liver cancer, Time to evolve trial design after everolimus failure. Nat Rev Clin Oncol, 11, 506-7. https://doi.org/10.1038/nrclinonc.2014.136
  12. Oishi N, Yamashita T, Kaneko S (2014). Molecular biology of liver cancer stem cells. Liver Cancer, 3, 71-84. https://doi.org/10.1159/000343863
  13. Ridge CA, McErlean AM, Ginsberg MS (2013). Epidemiology of lung cancer. Semin Intervent Radiol, 30, 93-8. https://doi.org/10.1055/s-0033-1342949
  14. Sawanyawisuth K, Wongkham C, Araki N, et al (2012). Serial analysis of gene expression reveals promising therapeutic targets for liver fluke-associated cholangiocarcinoma. Asian Pac J Cancer Prev, 13, 89-93.
  15. Wang H, Hou L, Li A, et al (2014). Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int, 2014, 864894.
  16. Wang H, Zhao LN, Li KZ, et al (2006). Overexpression of ribosomal protein L15 is associated with cell proliferation in gastric cancer. BMC Cancer, 6, 91. https://doi.org/10.1186/1471-2407-6-91
  17. Wilson-Edell KA, Kehasse A, Scott GK, et al (2014). RPL24, a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth. Oncotarget, 5, 5165-76.
  18. Xu HF, Chen L, Liu XD, et al (2014). Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis. Asian Pac J Cancer Prev, 15, 3045-50. https://doi.org/10.7314/APJCP.2014.15.7.3045

피인용 문헌

  1. Role of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells vol.18, pp.3, 2017, https://doi.org/10.3390/ijms18030547
  2. Vanadium complex: an appropriate candidate for killing hepatocellular carcinoma cancerous cells pp.1572-8773, 2018, https://doi.org/10.1007/s10534-018-0139-x